

To:

1. Head of Regional Province Health Service Office
2. Head of Regional Regency/City Health Service Office
3. Head/President Director/Director of Hospitals
4. Head of the Hospital Association of Indonesia
(*Perhimpunan Rumah Sakit Seluruh Indonesia* or “PERSI”)
5. Head of the Clinics Association of Indonesia
(*Ketua Asosiasi Klinik Indonesia* or “ASKLIN”)
6. Head of the Clinics Association and Primary Health Services Facility of Indonesia
(*Ketua Perhimpunan Klinik dan Fasilitas Pelayanan Kesehatan Primer Indonesia* or “PKFI”)
7. Head of the Health Service Office Association of Indonesia
8. Head of the Clinic Laboratory Union of Indonesia
(*Ketua Ikatan Laboratorium Klinik Indonesia* or “ILKI”)

throughout Indonesia

CIRCULAR LETTER
NUMBER: HK.02.02/I/2875/2020
REGARDING
MAXIMUM PRICING FOR ANTIBODY RAPID TEST EXAMINATION

One of the assets in handling COVID-19 in Indonesia is the utilization of the Anti Gen Rapid Test and/or Antibody Rapid Test for cases of contact from confirmed COVID-19 patients. Antigen Rapid Test and Antibody Rapid Test can also be used to indicate the existence of a COVID-19 infection amongst groups of OTG (*Orang tanpa Gejala* or Persons without Symptoms), ODP (*Orang dalam Pemantauan* or Persons under Observation), and PDP (*Pasien dalam Pengawasan* or Patients under Observation) in an area that does not have facilities for an RT-PCR examination or does not have a media to retrieve specimens (Swab and/or VTM). Rapid Test examinations acts only as an initial indicator, the examination results of a Rapid Test must be confirmed using an RT-PCR. On the contrary, an RT-PCR examination does not require a prior Rapid Test examination.

Antibody Rapid Test is widely practiced in public before conducting domestic travel activities. Antibody Rapid Tests can be conducted in a Health Service Facility or outside of a Health Service Facility if it is conducted by a Health Worker. The various prices in conducting a Rapid Test examination may cause public confusion. Therefore, the Government’s role is required in dealing with the issue of Antibody Rapid Test examination so that the public will not be exploited for the purpose of obtaining profit.

This circular letter is intended to provide certainty to the public and the Antibody Rapid Test service providers so that the current pricing will guarantee ease of access in obtaining Antibody Rapid Test services for the public.

Considering:

1. Law Number 36 of 2009 on Health (State Gazette of the Republic of Indonesia of 2009 Number 144, Additional State Gazette of the Republic of Indonesia Number 5063);
2. Law Number 30 of 2014 on Government Administration (State Gazette of the Republic of Indonesia of 2014 Number 292, Additional State Gazette of the Republic of Indonesia Number 5601);
3. Government Regulation Number 21 of 2020 on Large Scale Social Restriction to Accelerate the Handling of the Corona Virus Disease 2019 (COVID-19) (State Gazette of the Republic of Indonesia of 2020 Number 91, Additional State Gazette of the Republic of Indonesia Number 6487);
4. Presidential Decree Number 11 of 2020 on the Stipulation of the Corona Virus Disease 2019 (COVID-19) as a Public Health Emergency;
5. Presidential Decree Number 12 of 2020 on the Stipulation of Non-Natural Disaster of the Spreading of the Corona Virus Disease 2019 (COVID-19) as a National Disaster;
6. Minister of Health Decree Number HK.01.07/MENKES/247/2020 on the Guidelines for Prevention and Control of the Corona Virus Disease 2019 (COVID-19);

With respect to the above, the relevant parties should instruct health service facilities to provide Antibody Rapid Test examination in accordance with a maximum pricing limitation in consideration of the following:

1. Maximum Pricing for the examination of an Antibody Rapid Test is in the amount of Rp.150,000,- (One Hundred Fifty Thousand Rupiah).
2. The maximum pricing as mentioned in number 1 is applicable to persons who are conducting a voluntary Antibody Rapid Test examination.
3. The Antibody Rapid Test examination is conducted by a competent Health Worker from a Health Service Facility.

4. The Health Service Facility or parties providing services of Antibody Rapid Test examination shall comply with the stipulated maximum pricing.

Therefore, this Circular Letter is conveyed to be implemented according to its intended purposes.

Stipulated in Jakarta

Date: July 6, 2020

DIRECTOR GENERAL OF HEALTH SERVICES

(Signed and Stamped)

BAMBANG WIBOWO

Copies of this Circular Letter is submitted to:

1. Minister of Health
2. Secretary General of the Ministry of Health
3. Head of the Indonesian National Board for Disaster Management